GGrantIndex
← Search

Biodegradable Polymerized Simvastatin

$186,334R21FY2014EBNIH

University Of Kentucky, Lexington KY

Investigators

Linked publications & trials

Abstract

DESCRIPTION: Synthetic degradable polymers are commonly used for drug delivery and to aid in tissue regeneration. Drugs are routinely encapsulated in the material for subsequent diffusion- and/or degradation-mediated release. Limitations with encapsulation, however, include limited payload and the potential for premature exhaustion of the delivery system. To prolong release, drugs have been conjugated to polymers. Drug can be attached to the polymer via a linker that subsequently releases the molecule following cleavage, or it can be incorporated into the polymeric backbone during synthesis. The overarching goal of this project is to develop and characterize a polymer synthesized using drug molecules, in the present case simvastatin, as monomers. The working hypothesis is that the structure of simvastatin, with a lactone moiety in the prodrug, is amenable to ring-opening polymerization. As such, polymerized simvastatin could then be processed into films that degrade by hydrolysis to release bioactive simvastatin molecules, which have osteogenic, anti-inflammatory, and angiogenic properties in addition to their well-known known hypolipidemic effects. Aim 1 will develop and characterize a degradable, polymerized form of simvastatin. With respect to this objective, it is hypothesized that the polymer can be processed into biodegradable films that release simvastatin. Aim 2 will investigate whether polymerized films of simvastatin degrade in vivo to stimulate osteogenesis in a rodent supracalvarial implantation model. It is hypothesized that, as the polymer degrades, bioactive simvastatin is released to enhance local bone formation. If the proof-of-principle studies proposed for this Exploratory/Developmental Award are successful, the polymer may be fabricated into a variety of physical forms (e.g., microspheres and tissue engineering scaffolds) to exploit the pleiotropic effects of simvastatin for bone and other tissue applications, as well as the methods potentially being applicable to other members of the statin family.

View original record on NIH RePORTER →